

A

Table with 4 columns: DBLMSP DBL variants, DNA, Protein, and Boundaries. Rows include variants like 3D7, 7G8, Dd2, FCR3, FCR3, P. reichenowi, and various isolates (002, 017, 026, 067, 028, 384).

Table with 4 columns: DBLMSP2 DBL variants, DNA, Protein, and Boundaries. Rows include variants like 3D7, Isolate 020, Isolate 023, Isolate 028, Isolate 082, Isolate 093, Isolate 097, and Isolate 384.

B

Table with 2 columns: Variant names (Dd2, FCR3, Isolate067, Isolate002, Isolate017, P. reichenowi, Isolate384, Isolate028, Isolate026) and their corresponding protein sequences.

Table with 2 columns: Variant names (Dd2, FCR3, Isolate067, Isolate002, Isolate017, P. reichenowi, Isolate384, Isolate028, Isolate026) and their corresponding protein sequences, with a red box highlighting a specific region.

Table with 2 columns: Variant names (Dd2, FCR3, Isolate067, Isolate002, Isolate017, P. reichenowi, Isolate384, Isolate028, Isolate026) and their corresponding protein sequences, with a red box highlighting a specific region.

C

Table with 2 columns: Variant names (3D7, Isolate384, Isolate093, Isolate097, Isolate023, Isolate082, Isolate028, Isolate020) and their corresponding protein sequences.

Table with 2 columns: Variant names (3D7, Isolate384, Isolate093, Isolate097, Isolate023, Isolate082, Isolate028, Isolate020) and their corresponding protein sequences.

Table with 2 columns: Variant names (3D7, Isolate384, Isolate093, Isolate097, Isolate082, Isolate028, Isolate020) and their corresponding protein sequences.

Figure S1. Details of the DBLMSP and DBLMSP2 DBL domains used for functional analysis

A. DNA and protein accession numbers of the different DBL domains used in this study. The amino-acid boundaries of each DBL domain are indicated in the right-hand column. **B.** Sequence alignment of the DBLMSP DBL domains. A common feature of the two DBL domains that do not bind IgM (7G8 and isolate 028) is the presence of a Glu amino-acid residue at position 310, where all other domains contain either a His or an Ala residue. To test whether we could narrow the binding site to IgM even further, we used site-directed mutagenesis and substituted the Glu and Leu present at positions 310-311 in the non-binding domain of isolate 028 for Ala and Gln residues present in the binding domain of isolate 384 (red box). These substitutions were however not sufficient to restore binding of the DBL domain of isolate 028 to human IgM, suggesting that these two residues are not sufficient to confer the IgM-binding property. **C.** Sequence alignment of the DBLMSP2 DBL domains. Sequence alignments of the different DBL variants were performed with ClustalW2 (<http://www.ebi.ac.uk/Tools/msa/clustalw2/>) and displayed using Boxshade (http://embnet.vital-it.ch/software/BOX_form.html).




Figure S2. Modelled structural comparisons between IgM-binding and -non-binding DBL domains

The structures of the IgM-binding DBL domains from DBLMSP and DBLMSP2 were modelled using the Phyre2 software and the known crystal structure of the DBL domain from DBLMSP2. The IgM-binding DBL domain models are shown in beige, and the regions that differ in the non-binding DBL domains (isolate 028 and strain 7G8 in DBLMSP), are superimposed and highlighted in red (left panel). The right panel shows a 180° rotation of the same structure. Most differences were observed in helices h1, h2a, h4 and h7. Polymorphisms in h7 are, however, also frequently observed around the same positions amongst DBL domains that have retained their IgM-binding ability. The IgM-binding site is therefore most likely to be in helices h1, h2a or h4.